Procainamide Hydrochloride

Atrial Fibrillation, life-threatening ventricular arrhythmias, Supraventricular Arrhythmias + 1 more
Treatment
16 Active Studies for Procainamide Hydrochloride

What is Procainamide Hydrochloride

ProcainamideThe Generic name of this drug
Treatment SummaryProcaine is a medication related to anesthetics. This derivative of procaine has a weaker effect on the central nervous system.
Procainamide Hydrochlorideis the brand name
Procainamide Hydrochloride Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Procainamide Hydrochloride
Procainamide
1976
29

Effectiveness

How Procainamide Hydrochloride Affects PatientsProcainamide is used to produce numbing, local or regional anesthesia, and to treat irregular heartbeats, such as those caused by surgery, cardiac manipulation, heart attack, digitalis toxicity, or other heart conditions. It works by reducing the excitability of the ventricles and increasing the amount of stimulation they need in order to contract. The sinoatrial node is not affected by procainamide.
How Procainamide Hydrochloride works in the bodyProcainamide is a drug that numbs the nerves. It does this by blocking the pathways that allow electrical signals to travel between cells, which stops the nerve from firing and thus numbing the area.

When to interrupt dosage

The proposed dosage of Procainamide Hydrochloride varies depending on the recognized condition, such as Supraventricular Arrhythmias, Ventricular Tachycardia and life-threatening ventricular arrhythmias. The measure is contingent upon the technique of implementation (e.g. Capsule, gelatin coated or Injection, solution - Intramuscular; Intravenous) featured in the following table.
Condition
Dosage
Administration
Atrial Fibrillation
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral
life-threatening ventricular arrhythmias
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral
Supraventricular Arrhythmias
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral
Ventricular Tachycardia
, 500.0 mg/mL, 100.0 mg/mL, 500.0 mg, 375000.0 mg, 250.0 mg, 375.0 mg, 750.0 mg, 1000.0 mg
, Intramuscular; Intravenous, Injection, solution, Injection, solution - Intramuscular; Intravenous, Solution, Solution - Intramuscular; Intravenous, Oral, Capsule, Capsule - Oral, Liquid, Liquid - Intramuscular; Intravenous, Tablet, extended release, Tablet, extended release - Oral, Injection, Injection - Intramuscular; Intravenous, Tablet, film coated, extended release, Tablet, film coated, extended release - Oral, Capsule, gelatin coated, Capsule, gelatin coated - Oral, Tablet, film coated, Tablet, film coated - Oral

Warnings

Procainamide Hydrochloride has three contraindications. It should not be taken while having any of the conditions outlined in the table below.Procainamide Hydrochloride Contraindications
Condition
Risk Level
Notes
Lupus
Do Not Combine
Complete Heart Block
Do Not Combine
Torsades de Pointes
Do Not Combine
There are 20 known major drug interactions with Procainamide Hydrochloride.
Common Procainamide Hydrochloride Drug Interactions
Drug Name
Risk Level
Description
Arsenic trioxide
Major
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Arsenic trioxide.
Artemether
Major
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Artemether.
Asenapine
Major
The risk or severity of QTc prolongation can be increased when Procainamide is combined with Asenapine.
Clofarabine
Major
The serum concentration of Clofarabine can be increased when it is combined with Procainamide.
Dalfampridine
Major
The serum concentration of Dalfampridine can be increased when it is combined with Procainamide.
Procainamide Hydrochloride Toxicity & Overdose RiskThe toxic dose of a drug in rats when injected intravenously is 95 mg/kg, 312 mg/kg when given orally to mice, 103 mg/kg when injected intravenously to mice, and 250 mg/kg when injected intravenously to rabbits.

Procainamide Hydrochloride Novel Uses: Which Conditions Have a Clinical Trial Featuring Procainamide Hydrochloride?

Seventeen active trials are assessing the potential of Procainamide Hydrochloride to ameliorate life-threatening Ventricular Tachycardia, ventricular arrhythmias and pre-excited Atrial Fibrillation.
Condition
Clinical Trials
Trial Phases
Ventricular Tachycardia
13 Actively Recruiting
Not Applicable, Phase 3, Phase 2, Early Phase 1
life-threatening ventricular arrhythmias
0 Actively Recruiting
Atrial Fibrillation
0 Actively Recruiting
Supraventricular Arrhythmias
0 Actively Recruiting

Patient Q&A Section about procainamide hydrochloride

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What class of drugs is procainamide?

"Procainamide is a medication used to treat heart rhythm problems, including ventricular arrhythmias, supraventricular arrhythmias, atrial flutter/fibrillation, and Wolf-Parkinson-White syndrome. It is in the antiarrhythmic Agent Class 1A class of medications."

Answered by AI

What is procainamide hydrochloride used for?

"Procainamide is used to treat abnormal heart rhythms. It helps to make your heart more resistant to abnormal activity."

Answered by AI

What is the most common adverse effects of procainamide?

"The most common side effects of Pronestyl are nausea, vomiting, loss of appetite, diarrhea, bitterness in the mouth, dizziness, tiredness, and itching or rash."

Answered by AI

What is another name for procainamide?

"PRONESTYL is a medication indicated for the treatment of ventricular arrhythmias, such as sustained ventricular tachycardia, that are considered life-threatening by a physician."

Answered by AI

Clinical Trials for Procainamide Hydrochloride

Have you considered Procainamide Hydrochloride clinical trials? We made a collection of clinical trials featuring Procainamide Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Medical University of Michigan in Ann Arbor, United States.

AI-Guided Ablation for Ventricular Tachycardia in Heart Disease

18+
All Sexes
Ann Arbor, MI
Over the last decade, radiofrequency catheter ablation (RFCA) has become an established treatment for ventricular arrhythmias (VA). Due to the challenging nature of visualizing lesion formation in real time and ensuring an effective transmural lesion, different surrogate measures of lesion quality have been used. The Ablation Index (AI) is a variable incorporating power delivery in its formula and combining it with CF and time in a weighted equation which aims at allowing for a more precise estimation of lesion depth and quality when ablating VAs. AI guidance has previously been shown to improve outcomes in atrial and ventricular ablation in patients with premature ventricular complexes (PVC). However research on outcomes following AI-guidance for VT ablation specifically in patients with structural disease and prior myocardial infarction remains sparse. The investigators aim at conducting the first randomized controlled trial testing for the superiority of an AI-guided approach regarding procedural duration.
Recruiting
Has No Placebo
Medical University of Michigan (+5 Sites)Alexander Mazur, MDBiosense Webster, Inc.
Image of CardioVascular Associates of Mesa in Mesa, United States.

CCM Device for Heart Failure

18+
All Sexes
Mesa, AZ
The goal of this clinical trial is to demonstrate that the OPTIMIZER® Integra CCM-D System (the "CCM-D System") can safely and effective convert induced ventricular fibrillation (VF) and spontaneous ventricular tachycardia and/or ventricular fibrillation (VT/VF) episodes in subjects with Stage C or D heart failure who remain symptomatic despite being on guideline-directed medical therapy (GDMT), are not indicated for cardiac resynchronization therapy (CRT), and have heart failure with reduced left ventricular ejection fraction (LVEF ≤40%). Eligible subjects will be implanted with the CCM-D System. A subset of subjects will be induced into ventricular fibrillation "on the table" in the implant procedure room. During the follow-up period, inappropriate shock rate and device-related complications will be evaluated. The follow-up period is expected to last at least two years.
Waitlist Available
Has No Placebo
CardioVascular Associates of Mesa (+66 Sites)Niraj Varma, MD, PhDImpulse Dynamics
Have you considered Procainamide Hydrochloride clinical trials? We made a collection of clinical trials featuring Procainamide Hydrochloride, we think they might fit your search criteria.Go to Trials
Image of Cedars Cancer Center, McGill University Health Centre in Montreal, Canada.

Ablative Radiation for Ventricular Tachycardia

18+
All Sexes
Montreal, Canada
In 2017 a novel treatment approach to a series of 5 patients with refractory VT was introduced, using ablative radiation with a stereotactic body radiation therapy (SBRT) technique to arrhythmogenic scar regions defined by noninvasive cardiac mapping. More recently, Robinson et al. reported on the results of their Electrophysiology-Guided Noninvasive Cardiac Radioablation for Ventricular Tachycardia (ENCORE-VT) trial, also using a similar SBRT technique in a series of 17 patients with refractory VT. Both studies report a marked reduction in VT burden, a decrease in antiarrhythmic drug use, and an improvement in quality of life. Since then, numerous other centres have detailed their initial experience with this technique. These initial results suggest that this new treatment paradigm has the potential to improve morbidity and mortality for patients suffering from treatment-refractory VT by means of a minimally invasive technique, but requires further validation for widespread use. The appropriate dose for therapeutic effect of this new treatment is not well established as only a single dose prescription of 25 Gy in 1 fraction has been described with benefit. In this phase 2 trial, the investigators plan on expanding the experience with this technique but also by contributing to understanding the relationship between dose-effect relationship through a dose de-escalation stratification, to 20 Gy in 1 fraction, with the goal of minimizing possible adverse events and radiation dose to surrounding healthy tissue while maintaining a clinical benefit.
Phase 2
Waitlist Available
Cedars Cancer Center, McGill University Health CentreMartin L Bernier, MD
Image of Nova Scotia Health Authority in Halifax, Canada.

SBRT for Ventricular Tachycardia

Any Age
All Sexes
Halifax, Canada
Ventricular tachycardia (VT) contributes to over 350,000 sudden deaths each year in the US. Malignant VTs involve an electrical "short circuit" in the heart, formed by narrow channels of surviving tissue inside myocardial scar. Current treatment for VT consists of either implantable defibrillators (ICDs), suppressive drug therapy, catheter ablation or a combination of all 3. Implantable Defibrillators (ICDs) reduce sudden death and can terminate some ventricular tachycardia (VT) without shocks, but they don't prevent VT. The occurrence of ≥1 ICD shock is associated with reductions in mental well-being and physical functioning, and increases in anxiety and sometimes depression. Further, ICD shocks have been consistently associated with adverse outcomes, including heart failure and death. Furthermore, the most important predictor of ICD shocks is a history of prior ICD shocks. Therapies to suppress VT include antiarrhythmic drug therapy and catheter ablation, neither however is universally effective. When VT recurs despite antiarrhythmic drug therapy and catheter ablation, novel yet invasive, approaches may be required. Such invasive procedures carry consequent risks of cardiac and extra-cardiac injury. Stereotactic body radiotherapy (SBRT) is a non-invasive technique that delivers high doses of radiation precisely to specified regions in the body, while minimizing exposure to adjacent tissue. This technique is currently, and commonly used in the treatment of cancer. Conventional application of SBRT has made use of its ability to spare non-target tissue, including for treatment of tumors near the heart. More recently, clinicians have changed the paradigm, by focusing radioablative energy on ventricular scar responsible for ventricular tachycardia. Pre-clinical studies have supported the concept and were followed by first-in-human VT therapeutic experience in 2017. Subsequent studies have had encouraging results for patients who failed or were unable to tolerate conventional treatment.
Recruiting
Has No Placebo
Nova Scotia Health AuthorityJohn Sapp, MD FRCPC
Have you considered Procainamide Hydrochloride clinical trials? We made a collection of clinical trials featuring Procainamide Hydrochloride, we think they might fit your search criteria.Go to Trials
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Terms of Service·Privacy Policy·Cookies·Security